Sunday , May 16 2021
Home / FT Alphaville / Get shorty: how Clinuvel Pharmaceuticals beat the hedgies

Get shorty: how Clinuvel Pharmaceuticals beat the hedgies

Summary:
The acrimonious battle between hedge fund short-sellers and Australian biopharma group Clinuvel Pharmaceuticals appears finally to be drawing to a close.After a two-year struggle, during which short-sellers have focused on the company’s regulatory hurdles for its drugs and its steep valuation, the hedgies are in retreat.Frequently the subject of debate on message boards and, improbably, a favourite stock of cigar-smoking German hedge fund manager Florian Homm, .1bn Clinuvel provides a treatment for erythropoietic protoporphyria. EPP is a rare and serious inherited disease that leads to raised levels of a phototoxic molecule. When a patient’s skin is exposed to light the molecule reacts, leading to irritation or a visible burning within minutes. At worst, the pain is so

Topics:
FT Alphaville considers the following as important:

This could be interesting, too:

Tyler Cowen writes Lies vs. silence?

Global Economic Intersection Analysis Blog Feed writes A Brief History Of The Buy-to-Build Indicator

Tyler Cowen writes Saturday assorted links

Greg Mankiw writes Testing the Mill Hypothesis

The acrimonious battle between hedge fund short-sellers and Australian...

FT Alphaville
FT Alphaville is a free daily news and commentary service giving finance professionals the information they need, when they need it. In a world where market professionals are inundated with information there is a pressing need to edit and filter, and hopefully sow a few ideas along the way. That’s where the FT Alphaville team comes in.

Leave a Reply

Your email address will not be published. Required fields are marked *